Related Experiment Video
Updated: Jun 28, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Evaluating Alkaline Phosphatase-Instructed Self-Assembly of d-Peptides for Selectively Inhibiting Ovarian Cancer
Meihui Yi1, Zhaoqianqi Feng1, Hongjian He1
1Department of Chemistry, Brandeis University, 415 South Street, Waltham, Massachusetts 02453, United States.
Abstract:
Cancer is a major public health concern requiring novel treatment approaches. Enzyme-instructed self-assembly (EISA) provides a unique approach for selectively inhibiting cancer cells. However, the structure and activity correlation of EISA remains to be explored. This study investigates new EISA substrates of alkaline phosphatase (ALP) to hinder ovarian cancer cells. Analogues 2-8 were synthesized by modifying the amino acid residues of a potent EISA substrate 1 that effectively inhibits the growth of OVSAHO, a high-grade serous ovarian cancer (HGSOC) cell line. The efficacy of 2-8 against OVSAHO was assessed, along with the combination of substrate 1 with clinically used drugs. The results reveal that substrate 1 displays the highest cytotoxicity against OVSAHO cells, with an IC50 of around 8 μM. However, there was limited synergism observed between substrate 1 and the tested clinically used drugs. These findings indicate that EISA likely operates through a distinct mechanism that necessitates further elucidation.
Insights
This study explored new enzyme-instructed self-assembly (EISA) substrates to target ovarian cancer. Substrate 1 showed significant cytotoxicity against high-grade serous ovarian cancer cells, suggesting a unique EISA mechanism.
Area of Science:
- Biochemistry
- Oncology
- Materials Science
Background:
- Cancer remains a significant global health challenge, necessitating innovative therapeutic strategies.
- Enzyme-instructed self-assembly (EISA) offers a promising avenue for targeted cancer cell inhibition.
- Understanding the structure-activity relationship of EISA is crucial for optimizing its therapeutic potential.
Purpose of the Study:
- To synthesize and evaluate novel EISA substrates targeting alkaline phosphatase (ALP) for ovarian cancer treatment.
- To investigate the structure-activity correlation of EISA substrates against high-grade serous ovarian cancer (HGSOC) cells.
- To assess the efficacy of a potent EISA substrate and its analogues against the OVSAHO cell line.
Main Methods:
- Synthesis of EISA substrate analogues (2-8) by modifying amino acid residues of a known potent EISA substrate (1).
- Evaluation of the cytotoxicity of synthesized analogues against the OVSAHO HGSOC cell line.
- Assessment of the synergistic effects of substrate 1 in combination with clinically approved drugs.
Main Results:
- Substrate 1 demonstrated potent cytotoxicity against OVSAHO cells, with an IC50 value of approximately 8 μM.
- Analogues 2-8 were synthesized and tested, but substrate 1 exhibited superior efficacy.
- Limited synergistic effects were observed when substrate 1 was combined with existing clinical cancer therapies.
Conclusions:
- EISA substrate 1 is a highly effective inhibitor of OVSAHO cell growth, highlighting its potential in ovarian cancer therapy.
- The distinct mechanism of action for EISA warrants further in-depth investigation.
- Future research should focus on elucidating the precise molecular pathways involved in EISA-mediated cancer cell death.
